• Male or female aged ≥ 18 years at the time of signing the informed consent.

• Eastern Cooperative Oncology Group (ECOG)-PS ≤ 2 at the time of the screening visit.

• Contraceptive use by male and female participants must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Male Participants:

• A male participant must agree to use a highly effective contraceptive as detailed in Appendix 4 of this protocol during the intervention period and for at least 12 months after the last dose of study intervention and refrain from donating sperm during this period.

• Female Participants:

• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

• Not a woman of childbearing potential (WOCBP) OR

• A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 12 months after the last dose of study intervention.

• Preparing to undergo allogeneic HCT for either of the following:

• AML

• MDS

• ALL

• Participants in the treatment arms must express HLA-A\*0201. Participants in the control arm may express any HLA type.

• Having the HA1+/- or HA-1+/+ (HA-1 positive) genotype to be eligible for TSC-100 treatment.

• Having the HA2+/- HA-2+/+ (HA-2 positive) genotype to be eligible for TSC-101 treatment.

• Having a haploidentical donor, MMUD, or MUD for HCT who is adequately HLA-matched by institutional standards and meets the donor inclusion criteria.

• Considered to be clinically indicated for haploidentical donor, MMUD, or MUD transplantation at the discretion of the treating investigator.

• Considered to be clinically indicated for RIC at the discretion of the treating investigator.

• Considered to be clinically indicated for peripheral blood stem cell transplantation at the discretion of the treating investigator.

• Organ function parameters for transplant eligibility are met per institutional standards.

• Capable of giving signed informed consent - which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

• Participants must provide consent for mandatory study procedures including bone marrow biopsy and blood sampling for research analyses in the ICF.

• Participants must agree to participate in long-term follow-up for up to 15 years post initial product treatment if they are enrolled in the study and receive the investigational Tcell infusion.

⁃ Donor Inclusion Criteria :

• Male or female aged ≥ 18 years at the time of signing the informed consent.

• Able to undergo peripheral blood stem cell (PBSC) collection and up to 2 rounds of leukapheresis (for TSC-100 or TSC101 manufacturing for treatment arms only, and f for stem cell collection for both treatment arms and the control arm).

• Donors matched to TSC-100 participants should be HA-1-/- (negative) and/or negative for all HLA-A\*02 alleles

• Donors matched to TSC-101 participants should be negative for all HLA-A\*02 alleles

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.